"Superman" Urges Insurance Reform

5 February 1996

Superman star Christopher Reeve, who is paralyzed as a result of a riding accident in May 1995, has said that his disability insurance cannot continue covering the $400,000 hospital fees which his injuries are costing him a year, and is urging the government to approve reforms to health insurance legislation. Last week, the insurance industry came out against such reforms (see page 15).

Mr Reeve said his insurance policy, taken out 20 years ago, has a lifetime limit on payments of $1.2 million, and this is now running out. While a year or two ago he and his family appeared to be very well off, the picture has now changed, the actor said, adding that the position is much worse for many other people.

Mr reeve is calling for abolition of lifetime limit amounts on such insurance, and says that spreading the cost of covering the relatively few catastrophic cases such as himself would add only $8 on average to the cost of an insurance policy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight